Amyotrophic lateral sclerosis
Best reviews
​
2022: A good review on ALS looks at the involvement of the endocannabinoid system in the regulation of the lipids
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine
https://pubmed.ncbi.nlm.nih.gov/36345044
​
2019: Cannabis in mouse models of ALS
Effects of cannabinoids in Amyotrophic Lateral Sclerosis (ALS) murine models: a systematic review and meta-analysis
https://pubmed.ncbi.nlm.nih.gov/30520038/
​
2016: A review of ALS and the cannabinoids
Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?
https://www.ncbi.nlm.nih.gov/pubmed/28197175
​
2015: A book chapter by Dr. Pertwee
Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis
https://pubmed.ncbi.nlm.nih.gov/26408162/
​
2010: Cannabis & ALS
Cannabis and amyotrophic lateral sclerosis: hypothetical and practical applications, and a call for clinical trials
http://www.ncbi.nlm.nih.gov/pubmed/20439484
​
2008: The ECS & ALS
The endocannabinoid system in amyotrophic lateral sclerosis
https://pubmed.ncbi.nlm.nih.gov/18781981/
​
2001: Carter’s review of why cannabis might be helpful for ALS
Marijuana in the management of amyotrophic lateral sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/11467101
​
Timeline of Research
​
2021: Former football player Steve Gleason, who has ALS, testified to Louisiana lawmakers about how medical marijuana saved him from a “downward spiral” of side effects from prescription medications
​
2020: In humans with ALS, their blood levels of AEA, 2-AG & 2-OG were predictive of their disease state (66 patients)
Endocannabinoids and related lipids in serum from patients with amyotrophic lateral sclerosis
https://pubmed.ncbi.nlm.nih.gov/33094490/
​
2019: In humans with ALS, a combination of THC & CBD found helpful (32 patients in a retrospective mono-centric cohort study)
Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD)
https://www.ncbi.nlm.nih.gov/pubmed/31493784
​
2017: In tissue model of ALS, CBD changed genes related to ALS pathology, oxidative stress, mitochondrial dysfunction, and excitotoxicity
Gingival Stromal Cells as an In Vitro Model: Cannabidiol Modulates Genes Linked With Amyotrophic Lateral Sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/27714895
​
2017: A case study of using CBD for ALS
[Self-medication with cannabidiol oil in a patient with primary lateral sclerosis]
https://www.ncbi.nlm.nih.gov/pubmed/28397674
​
2014: In a mouse model of ALS, help seen for ALS with Sativex via upregulation of CB2
Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/24703394
​
2010: In a mouse model of ALS, CB1 receptors very sensitive for controlling glutamate and GABA levels
Abnormal sensitivity of cannabinoid CB1 receptors in the striatum of mice with experimental amyotrophic lateral sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/19452308
​
2008: In a mouse model of ALS, evidence for changes in level of CB1 & AMPA receptors
Altered presymptomatic AMPA and cannabinoid receptor trafficking in motor neurons of ALS model mice: implications for excitotoxicity
https://www.ncbi.nlm.nih.gov/pubmed/18279310
​
2007: In a mouse model of ALS, CB2 agonist slowed degeneration and preserved motor function
The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset
https://www.ncbi.nlm.nih.gov/pubmed/17241118
​
2006: In human spinal cords, the glial cells activated in MS & ALS show more COX2, P2X7 & CB2 – agonists suggested as therapeutic
COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord
https://www.ncbi.nlm.nih.gov/pubmed/16512913
​
2006: In a mouse model of ALS, synthetic and genetic methods to increase endocannabinoid levels show help for ALS
Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice
https://www.ncbi.nlm.nih.gov/pubmed/16571781
​
2006: In a mouse model of ALS, a synthetic CB1 agonist delays disease progress
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/16781706
​
2005: In mice, CBN as a significant tool against ALS
Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival
https://www.ncbi.nlm.nih.gov/pubmed/16183560
​
2004: In mice, efficacy of THC to attenuate excitotoxic and oxidative cell damage
Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid
https://www.ncbi.nlm.nih.gov/pubmed/15204022
​
2004: A small survey of cannabis users found it might be helpful for ALS
Survey of cannabis use in patients with amyotrophic lateral sclerosis
https://www.ncbi.nlm.nih.gov/pubmed/15055508
​